Symposium 3 Antibody therapy for disorders of thrombosis and hemostasis

[SY3-4] Caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

Flora Peyvandi (Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Universit degli Studi di Milano, Italy)

Flora Peyvandi is Professor of Internal Medicine at the University of Milan and the Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy. She received her medical degree from the University of Milan, is certified in Haematology and was awarded PhDs from the Maastricht University, The Netherlands and the University of Milan for her research in the field of rare bleeding disorders.Dr Peyvandi's basic and medical science research has focussed on the investigation of coagulation disorders. Her research in the prevalence and mechanism of coagulation disorders has as its objective the development of cost effective treatment for the widespread treatment of patients. Previous research has encompassed genotype and phenotype studies of thrombotic and haemorrhagic disorders. She has contributed extensively to the study of RBDs, rarely diagnosed and poorly characterised due to their low frequency. She has published extensively on this group of disorders and developed international registries with the aim of harmonising internationally the diagnosis and classification of RBDs. She has also set up an international collaboration on microangiopathies, rare thrombotic disorders, which can be difficult to diagnose and therefore treat. By coordinating a variety of studies Dr. Peyvandi has made the Milan centre one of the major contributors to research in the area of thrombotic thrombocytopenic disorders.Recently her research has been focused on the study of risk factors for the development of inhibitors in haemophilia and on the ‘next-generation’ DNA sequencing to understand the genetic predisposition to thrombotic and haemorrhagic disorders.